Lowering Drug Prices – Without Causing Harm

 

The primary axiom of the Hippocratic Oath taken by doctors is “First, do no harm.” This is important to remember when taking steps to lower drug prices.

Scott W. Atlas, writing in The Wall Street Journal, reminds us of this axiom and points out the benefits to Americans of those high drug prices we pay. Among these benefits are the following:

  • Early access to lifesaving drugs – Between 1995 and 2005, 12 new cancer drugs were first introduced in the U.S. versus 13 introduced in Canada, France, Germany, Japan, Switzerland and the United Kingdom combined!
  • More new drugs available – Of the 45 novel drugs the Food and Drug Administration approved in 2015, 29 were available in the U.S. first. A 2017 study found that all 45 approved new caner drugs were covered by Medicare in the U.S. compared with pubic insurance coverage of only 26 in the U.K., 19 in France, 13 in Canada and 11 in Australia.
  • Superior treatment results –America has superior treatment results for virtually all serious diseases reliant on drug treatment, including cancer, heart disease, stroke, high blood pressure and diabetes.

 

Bad Ideas for Lowering Drug Prices

None of this is to suggest that drug prices could not be lower than they are without giving up these benefits. But some of the suggested ways of lowering drug prices can cause greater harm than good. Here are some bad ideas that have been suggested:

  • Price Controls – Price controls have never been effective in controlling costs and prices in the past and usually lead to shortages. A 2014 study of 642 drug launches in 76 countries found that price regulation “strongly delays” them. A 2005 study estimated that drug price controls would have led to 198 fewer new drugs in the U.S. market from 1981 to 2000, at a societal cost of about $20 Trillion, or more than 28 times the estimated savings from those price controls.
  • Drug Prices Tied to Foreign Countries – This idea is supported by President Trump and Senator Bernie Sanders, unlikely allies, but both are misguided. Atlas says this would ultimately lead to the same consequences Europeans endure – reduced access to critical drugs and worse outcomes, including more deaths from disease. Why give up our advantages over the Europeans?
  • Price Negotiation by Medicare –It may seem logical that negotiation by a single dominant buyer would lower prices. But economists have concluded that would lead to supply shortages and fewer new products. Even worse, only the patient, not the negotiator, would suffer the severe penalties of sickness and death when drug availability and pharmaceutical innovation dries up. The U.K.’s National Health Service launched its 2017 Budget Impact Test which delayed any new drugs up to three years if projected spending exceeded benchmarks, regardless of effectiveness.

 

Good Ideas for Lowering Drug Prices

The Trump administration has proposed eliminating rebates paid by drug manufacturers to pharmacy benefit managers (PBMs), replacing them with discounts to beneficiaries at the point of sale. PBMs are middlemen who control formularies, the list of drugs covered by insurance plans. These rebates are payments for influence – either to position a drug on the formulary as “exclusive” or to give it preferred status over competitors.

Atlas explains: “PBMs act counter to patient interests while aggravating the lack of price transparency. These complex behind-the-scenes payments – $179 billion in 2016 – reward inflated list prices, on which patient premiums are often based. This prevents patients from taking account of price. Some PBMs even use contractual gag clauses to prohibit pharmacists from volunteering that a medication may be less expensive if purchased for cash – as it was in more than 20% of cases, according to a 2018 study.”

Atlas calls this proposal necessary but insufficient. He believes there is insufficient transparency in drug pricing to allow consumers maximum benefit. Rather, he would eliminate PBMs entirely. He says it would be better to require patients to pay directly for more of their drugs and reward them for saving money. Cheaper, higher-deductible drug insurance, coupled with larger, liberalized-use health savings accounts, would accomplish both goals – especially for seniors. HSAs are currently prohibited for seniors.

 

Other measures needed include:

  • Reducing barriers to the supply of new and competing drugs
  • Shortened clinical trials to reduce costs and speed drugs to the market

 

The importance of drugs to combat diseases cannot be overstated. The most significant progress in extending life expectancy has come from new drugs. We must avoid policies that undermine this progress while providing lower cost drugs the public can afford.

Science is Never Settled

 

Scientists and doctors are always learning.

When I began my medical school education 44 years ago, the Dean of the Medical School told us, “Half of what we’ll teach you in the next four years is wrong. But we don’t know which half.”She made this statement to emphasize the importance of viewing medicine as a life-long education – not just four years.

Many political activists insist that “the science is settled” whenever anyone pushes back against their so-called scientific conclusions. They dare you to challenge their interpretation of science whenever it threatens their political agenda. But real scientists and doctors know we are always learning and making new discoveries about the scientific world.

This truth was brought home recently in a powerful way for one family. Jaime Herrera Beutler is the Congressional representative of Washington’s Third Congressional District. She told her story in a recent Op-ed to the Wall Street Journal.

Beutler and her husband faced every expectant mother’s nightmare. When they went to her obstetrician for her 20-week ultrasound, the doctor told her their unborn baby had no chance for survival. The baby had no kidneys. Bilateral renal agenesis, or Potter’s Syndrome, usually results in miscarriage or suffocation at birth because the lungs don’t develop.

Their doctors said there was no solution to this situation and most women in this situation would terminate the pregnancy by abortion. But Beutler and her husband refused to get an abortion.

They prayed and looked for other medical opinions. They tried something that had never been done before: saline infusions in utero to mimic amniotic fluid, which stimulates lung development. Their baby successfully developed lungs even without kidneys and today their daughter, Abigail, is a happy, healthy girl who tells her mother she wants to eventually be Speaker of the House of Representatives!

Their doctors were wrong – because the current level of knowledge of this condition was incomplete. New methods of treatment led to new discoveries and new knowledge – further proof that science is never settled.

Last year I wrote about this in Settled Science Fiasco Remembered, a 50-year look back at the false scientific claims of Stanford biologist Paul Ehrlich. Ehrlich wrongly predicted a global cataclysm in his book, The Population Bomb,because he believed the earth could not sustain the growing population. Ehrlich erroneously concluded the “carrying capacity” of the Earth was “settled science.”

The happy ending to Rep. Beutler’s pregnancy nightmare is critical to remember when politicians want to push abortion even into the third trimester – or, gasp!, even after birth – as recently debated in the Virginia legislature. Every life is precious in God’s sight and should be in ours as well.

Human Organ Harvesting in China

 

If you need a new kidney in the U.S., the average waiting time is 679 days. If you need a new liver, the average waiting time is 239 days. These statistics are from the 2017 Milliman Report on organ transplant availability.

But in China– if you’ve got the money – the wait may only be a few days! How could this be possible?

The answer appears to be involuntary organ donations – from prisoners of conscience (Falun Gong members, Uighur Muslims, Tibetan Buddhists and “underground” Christians) according to Benedict Rogers, deputy chairman of the U.K. Conservative Party’s Human Rights Commission and an adviser to the International Coalition to End Transplant Abuse in China, writing in The Wall Street Journal.

These crimes are difficult to prove since the victims’ bodies are disposed of and the only witnesses are the doctors and prison guards involved. Naturally, the Chinese government is not forthcoming.

Rogers describes an undercover operation led by former Canadian politician and prosecutor David Kilgour, attorney David Matas, American journalist Ethan Gutmann and a team of researchers that posed as patients in Chinese hospitals. They say Dr. Huang Jiefu, China’s former vice minister for health and chairman of its organ-transplant committee, ordered two sparelivers as backups for a 2005 medical operation. They were delivered the next morning. In other words, three prisoners died to guarantee one patient a new liver.

In 2016, these investigators published a report, “Bloody Harvest/the Slaughter: An Update,” which summarized their work since 2006. This update estimated that between 60,000 and 100,000 organs are transplanted each year in Chinese hospitals.

Chinese officials tout “the largest voluntary organ donation system in Asia” and claim to have stopped prisoner donations in 2015. But Rogers is skeptical, noting the lack of any tradition of voluntary organ donation. In 2010 only 34 people donated their organs and even in 2018 the official number was only 6,000 donors who supposedly donated 18,000 organs. But this is far from the number of organs being transplanted as estimated by the “Bloody Harvest” researchers. The authors have confirmed that 712 hospitals in China carry out liver and kidney transplants.

Even death-row inmates cannot explain the number of transplants. China executes more people than the rest of the world combined but still only a few thousand a year. Since Chinese law requires prisoners be executed within seven days of sentencing, there is not enough time to match their organs to patients on the organ donor waiting list and have them ready for transplant.

The obvious conclusion is that involuntary donations of organs by prisoners of conscience continues, despite Chinese official denials. Israel, Taiwan and Spain have banned “organ tourism” to China. United Nations officials have called China to account for the sources of their organs but have received no response. The price of political dissent can be very high in China.